Silexion Therapeutics Corp (SLXN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Silexion Therapeutics Corp  (NASDAQ: SLXN)


Silexion Therapeutics's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Silexion Therapeutics's ROI in the second quarter of 2026?
Silexion Therapeutics Corp achieved a return on average invested assets (ROI) of 195.75 % in its second quarter of 2026, this is above SLXN's average return on investment of 188.13%.
Silexion Therapeutics Corp invested over the 12 months ending in its second quarter of 2026 $4 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 8 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 19 to 23.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 1312.3 % 1953.35 % - 105.58 % -91.44 %
Y / Y Net Income Change TTM -52.26 % 24.31 % 37.71 % -44.67 % -
Investment (TTM) in Millions 0 1 4 9 4
Return On Investment (TTM) 195.75 % 295.52 % 208.57 % 159.82 % 5790.32 %
SLXN's Overall Ranking # 23 # 19 # 30 # 3461 # 30
Seq. Investment Change TTM -19.82 % -23.51 % 58.66 % 1351.51 % 16.57 %
Seq. Net Income Change TTM -46.89 % 8.38 % 107.06 % -59.94 % 38.28 %
Net Income (TTM) in Millions 7 13 12 6 14

SLXN Company Profile >> Back to SLXN Roi Comparisons >> See Annual SLXN Return On Investment



Return On Investment SLXN's Ranking
Within: No.
Industry # 2
Sector # 9
Overall # 23

Return On Investment Statistics
High Average Low
376.46 %
188.13 %
87.06 %
(Jun 30 2025)   (Sep 30 2025)







Financial Statements
Silexion Therapeutics's II. Quarter Investments $ 0 Millions SLXN's Balance sheet
Silexion Therapeutics's II. Quarter Income $ -4 Millions Quarterly SLXN's Income Statement
SLXN's Income by Division See SLXN's Income by Division


SLXN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024


Total Investments in Millions 3 -4 0 0 0
Y / Y Investment Growth - - - - -
Net Income in Millions 12 17 0 0 0
Y / Y Net Income Growth -28.22 % - - - -
Annual Return On Investment 457.63 % - - - -


Annual Roi Comment
Despite deterioration in net income, company improved ROI to in the fiscal year 2025, company improved ROI to 457.63 % compare to previous year.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SLXN's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SLXN's Competitors
Subscribers only: Roi for Silexion Therapeutics's Suppliers
Subscribers only: Return On Investment for SLXN's Customers

Other Ratios
SLXN's Roa SLXN's Inventory Turnover Ratio SLXN's Growth Rates SLXN's Dividend Statistics
SLXN's Profitability Ratios SLXN's Asset Turnover Ratio SLXN's Dividend Growth
SLXN's Roe SLXN's Valuation Ratios SLXN's Financial Strength Ratios SLXN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %

Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.